Related Experiment Video
Updated: May 20, 2026
12:58
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Current state of Clostridium difficile treatment options
Anilrudh A Venugopal1, Stuart Johnson
1St John Hospital and Medical Center and Wayne State University School of Medicine, Detroit, Michigan, USA.
Summary
Standard Clostridium difficile infection (CDI) treatments face challenges from reduced efficacy and recurrence. New therapies are needed for recurrent and severe CDI cases, as resistance may limit current options.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Clostridium difficile infection (CDI) presents a growing clinical challenge due to reduced response to standard therapies.
- High rates of recurrent CDI occur with all current treatment agents, complicating patient management.
- Existing guidelines recommend metronidazole for mild/moderate CDI and vancomycin for severe cases.
Purpose of the Study:
- To review current treatment options for Clostridium difficile infection.
- To evaluate emerging therapies and strategies for managing recurrent and severe CDI.
- To identify the need for novel treatments in light of treatment resistance and recurrence.
Main Methods:
- Literature review of recent reports and clinical trials on CDI therapies.
- Analysis of treatment efficacy for standard agents like metronidazole and vancomycin.
- Assessment of alternative agents including nitazoxanide, teicoplanin, rifaximin, and tigecycline.
- Evaluation of resistance patterns affecting agents like fusidic acid, bacitracin, and rifaximin.
Main Results:
- Nitazoxanide and teicoplanin show potential as alternative CDI therapies in small trials.
- Rifaximin has demonstrated success in managing multiple CDI recurrences in uncontrolled studies.
- Tigecycline is anecdotally reported as beneficial for severe, complicated CDI.
- Emerging resistance to fusidic acid, bacitracin, and potentially rifaximin may limit their clinical utility.
Conclusions:
- Current standard therapies for Clostridium difficile infection are facing challenges.
- Limited clinical evidence exists for treating multiple CDI recurrences and severe complicated cases.
- There is a significant need for the development of new treatments and management strategies for CDI.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...